Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoproliferative Disorders 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

fludarabine 6Tacrolimus 6Busulfan 6blinatumomab 5Rituximab 5Cyclophosphamide 5fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Epoetin Alfa 4venetoclax 3Whole-Body Irradiation 3Methotrexate 3Darbepoetin alfa 3Alemtuzumab 3ponatinib 2ibrutinib 2entrectinib 2alectinib 2Thiotepa 2Therapeutics 2Patient Reported Outcome Measures 2Mesna 2Melphalan 2Everolimus 2Early Intervention, Educational 2Bone Marrow Transplantation 2Antilymphocyte Serum 2vandetanib 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoproliferative Disorders × phenethyl isothiocyanate × Other hematologic neoplasm × Clear all
NCT00968461 2013-04-15

Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders

M.D. Anderson Cancer Center

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡